Smooth sailing for NeuroDiscovery
Tuesday, 22 July, 2008
Perth biotech NeuroDiscovery has successfully completed an early stage trial of its neuropathic pain candidate NSL-043.
The compound, previously developed by another company for inflammatory disease, was successful in single ascending dose clinical trials and has now completed a multiple ascending dose trail.
The company said the compound's adverse event profile demonstrated good safety and tolerability.
NeuroDiscovery is also investigating the development of antagonists of the connexin and pannexin families of gap junction proteins.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...